Eli Lilly and Company (NYSE:LLY) Shares Sold by Bridges Investment Management Inc.

Bridges Investment Management Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 0.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,967 shares of the company’s stock after selling 59 shares during the period. Bridges Investment Management Inc.’s holdings in Eli Lilly and Company were worth $5,810,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Simon Quick Advisors LLC boosted its stake in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the period. Clear Harbor Asset Management LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $363,000. Liontrust Investment Partners LLP acquired a new stake in shares of Eli Lilly and Company in the 3rd quarter worth approximately $8,326,000. WASHINGTON TRUST Co lifted its stake in shares of Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock worth $11,013,000 after acquiring an additional 2,671 shares during the period. Finally, Armstrong Fleming & Moore Inc acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $357,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 34,538 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $631.81, for a total value of $21,821,453.78. Following the completion of the sale, the insider now owns 99,719,884 shares in the company, valued at approximately $63,004,019,910.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 195,055 shares of company stock worth $125,254,657. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Trading Up 2.7 %

Shares of LLY stock traded up $20.78 during trading hours on Wednesday, reaching $784.74. 843,909 shares of the stock traded hands, compared to its average volume of 3,182,437. Eli Lilly and Company has a 1-year low of $351.27 and a 1-year high of $800.78. The business has a fifty day moving average price of $742.32 and a 200 day moving average price of $642.33. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $745.63 billion, a PE ratio of 131.72, a PEG ratio of 1.67 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same quarter in the previous year, the business earned $2.09 earnings per share. The firm’s revenue was up 28.1% compared to the same quarter last year. On average, equities research analysts forecast that Eli Lilly and Company will post 12.42 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LLY shares. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 7th. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, Truist Financial reiterated a “buy” rating and issued a $850.00 target price on shares of Eli Lilly and Company in a report on Friday, March 22nd. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $700.00.

View Our Latest Analysis on LLY

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Featured Stories

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.